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Abstract  
Abstract  Acute myocardial infarction (AMI) is rarely associated with antiphospholipid syndrome. The treatment of these patients is a clinical 
challenge. We report the observations of 2 young adults (1 woman and 1 man), admitted in our acute care unit for acute myocardial infarction 
(AMI). A coagulopathy work-up  concludes the existence of antiphospholipid syndrome (APS) in the 2 cases.  APS syndrome was considered 
primary in 2 cases.  All patients presented an intense inflammatory syndrome (high level of CRP). Anticardiolipine was present in the 2 cases. 
However, anti B2 glycoprotein I antibodies were detected in only one case. Emergency percutaneous transluminal coronary angioplasty (PTCA) 
with direct stenting had been performed successfully only in the first case, and the follow-up was uncomplicated. Thereafter, long-term oral 
anticoagulant appeared to be effective. The last patient was admitted because of peripheral acute ischemia of legs. Standard electrocardiogram 
showed signs of previous silent anteroseptal wall myocardial infarction confirmed by echocardiography. The latter revealed an apical thrombus and 
a very low left ventricular ejection fraction.  Amputation of the right leg was necessary because of consultation occurred too late. However, he died 
four weeks later. Primary antiphospholipid syndrome should be considered as a cause of acute myocardial infarction in young adults, and PTCA 
with anticoagulant treatment is effective for initial treatment of this complication. 
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Introduction 
  
Antiphospholipid  syndrome  (APS)  is  an  autoimmune  disorder  of  acquired  hypercoagulability  characterized  by  the  association  of  vascular 
thromboses (venous, arterial, small vessels) and or pregnancy morbidity (foetal loss, premature birth or recurrent embryonic losses) and persistent 
elevated serum levels of Antiphospholipid antibodies (anticardiolipin, lupus anticoagulant or anti- B2glycoprotein I) [1] It is also considered as a 
multisystemic disorder with a wide spectrum of presentations cutting across all subspecialties of medicine. Acute myocardial infarction (AMI) is 
rarely associated with this syndrome with a frequency of approximately 4%. The treatment of these patients is a clinical challenge. Herein, we 
report two cases of antiphospholipid syndrome in young adults revealed by acute myocardial infarction. Written informed consent was obtained 
from the patients for publication of this case report and accompanying images 
  
  
Patients and case reports 
  
Case 1 
  
A 30 years old woman with a history of recurrent spontaneous abortion was admitted with severe midsternal chest pain, associated with sweating, 
nausea, and breathlessness. She had no risk factors for atherosclerosis (diabetes mellitus, hyperlipidaemia, hypertension, and smoking). She had 
never previously experienced chest pain at rest or on exertion. During physical examination, she was pale and sweaty with a tachycardia of 120 
beats/min. Her blood pressure was 80/40 mm Hg. There was no peripheral oedema and all peripheral pulses were present. She had a systolic 
apical murmur and symptoms of left heart failure. A 12 lead electrocardiogram revealed ST-segment elevation in leads V1, V2, V3, V4, V5, and V6. 
We diagnosed acute anterior myocardial infarction complicated by cardiogenic shock. Two-dimensional echocardiography revealed a markedly 
reduced left ventricular ejection fraction (30%) and akinesis of the anterior, lateral inferior wall, and inferior interventricular septum consistent with 
infarction in the left anterior descending area. Emergent coronary angiography was performed, the left anterior descending artery presented 
thrombosis and stenosis at the level of the proximal section (figure 1). Left ventriculography revealed that the left ventricle was dilated and 
markedly hypo kinetic. Therefore, percutaneous transluminal coronary angioplasty (PCTA) with direct stenting was performed, with successful 
recanalisation (figure 2). Serum creatine kinase peaked at 3500 U/l, haematological tests were normal, other laboratory tests of liver and renal 
functions and lipid profiles were normal. Anticoagulation by intravenous heparin infusion was performed for the next 10 days, Clopidogrel, aspirin, 
pravastatine were also administrated. Congestive heart failure was controlled by diuretics, nitrate, and low doses of dobutamine. 
  
We performed haematological tests for thrombotic disorders. Blood platelet count was 119 000 /ml and prothrombin time was normal. Levels of 
protein S, C, ATIII were normal. Lupus anticoagulant was negative. ACL were searched by for enzyme-linked immunosorbent assays (ELISA). ACL 
levels were expressed in IgM and IgG units with positive levels > 20 Units (U). Anti-2GPI antibodies (IgG and IgM) were also detected by ELISA. 
Anti-2GPI antibodies and ACL were detected at positive levels. The levels of Anticardiolipin antibodies (Ig M antibodies) and anti-B2-glycoprotein 
titres were 23.41 MPL and 26.74 U/ml respectively. 
  
There was no evidence for infection or any other triggering event before the MIs in this patient. Antinuclear antibodies and Anti DNA antibody were 
negative. Antiphospholipid antibodies tests repeated 12 weeks later remained positive. These findings satisfy the update Sapporo Classification 
criteria [1] for the diagnosis of antiphospholipid syndrome. This latter was considered primary because the patient had no signs of other systemic 
auto-immune diseases, particularly systemic lupus erythematosus (SLE). We decided to treat the patient with oral anticoagulation for life. The 
follow-up (24 months) was uncomplicated. Effort tests performed 3 and 6 months after PCTA were negative. 
  
Case 2 
  
A 30-year-old Caucasian man was admitted in our intensive care unit because of bilateral acute ischemia of the two legs. He was regularly treated 
for Basedow disease. Smoking was the only risk factor of atherosclerosis disease. Physical examination showed a skinny patient. Peripheral pulses 
of the legs were absent. Arterial pressure was normal. The electrocardiogram showed a QS pattern in leads V1, V2, V3, and V4. Echocardiography 
revealed  an  apical  large  thrombus  measuring  38  by  18  mm  associated  with  a  thinning  left  ventricular  wall,  suggesting  painless  myocardial 
infarction. It also demonstrated a markedly reduced left ventricular ejection fraction (19%) (Figure 3). The patient was immediately brought to the 
cardiovascular surgical department where bilateral Embolectomy to Fogarty probe was effectuated. Then amputation of the right leg was done 
because of so late consultation. Intravenous heparin was administrated with oral aspirin and clopidogrel. 
  
Haematological tests showed normal levels of C, S and ATIII Protein. While FT4, FT3 were high, TSH was low. The patient was found to have a 
positive Lupus anticoagulant LA and a false positive VDRL. Anticardiolipin antibodies were also tested and subsequently came back positive for 
anticardiolipin antibody of the IgM isotype with a low level (19.25 MPL). The patient had no evidence for infection or any other triggering event 
before the MIs. 
  
The patient was also found to have a false positive VDRL. Antinuclear antibodies, anti DNA, antiSm, anti SSA and anti SSB were negative. This was 
consistent with a primary antiphopholipid syndrome. Unfortunately, the patient died 15 days after his admission because of the failure of many of 
his organs (heart failure, acute renal failure, cytopenia). 
  
  
Discussion 
  
The most common features of thrombotic disorders in antiphospholipid syndrome are deep vein thrombosis, pulmonary thromboembolism, and 
stroke. This syndrome is rarely initiated in the coronary arteries. On the other hand, acute myocardial infarction is unusual in young adults, but it 
has been reported in patients with antiphospholipid syndrome. Page number not for citation purposes  3 
  
Antiphospholipid antibodies are the hallmark of the antiphospholipid syndrome which is characterized by thrombosis. It was first described in 
patients with systemic lupus erythmatosus and antiphospholipid antibodies [2]Antiphospholipid antibodies refer to auto antibodies that react to 
naturally occurring membrane bound phospholipids in human cells such as endothelial cells. These antibodies may be of IgG or IgM isotypes and 
consist of the lupus anticoagulant, anticardiolipin antibody, and false positive VDRL. 
  
Antiphospholipid antibodies are associated with autoimmune diseases such as systemic lupus erythematosus, Patients often exhibit positive lupus 
anticoagulant activity but they infrequently suffer from the typical systemic lupus erythematosus (SLE) that satisfies diagnostic criteria. When they 
occur  in  isolation,  this  is  known  as  primary  antiphospholipid  syndrome.  The  main  antiphospholipid  antibodies  implicated  in  thrombosis  and 
atherosclerosis are the anticardiolipin antibody, the lupus anticoagulant, and Ig G antibodies against plasma phospholipid –binding protein such as 
B2-glycoprotein I and prothrombin. Lupus anticoagulants were strong risk factors for both arterial and venous thrombosis and they are better 
predictors of thrombosis than anticardiolipin antibodies. Separate analysis of the different types of thrombosis showed anticardiolipin antibodies 
were associated with cerebral stroke and myocardial infarction but not with deep vein thrombosis. 
  
Anticardiolipin antibody isotypes and titers are 2 important issues. Most studies investigated only IgG antibodies or did not distinguish between 
isotypes. With these limitations, IgM anticardiolipin antibodies were not associated with thrombosis, which limits their value in clinical practice. 
Anti-b2-glycoprotein  I  antibodies  (anti-b2-GPI)  represent  one  of  the  main  subgroups  of  anticardiolipin  antibodies  (aCL)  associated  with 
antiphospholipid syndrome (APS). Positivity for anti-beta-2-glycoprotein I (anti-B2GPI) has been shown to be more closely associated with clinical 
manifestations of APS, including thrombosis. 
  
Our two patients had both positive Ig M Anticardiolipin antibodies in a low level, but one had positive anti-B2-glycoprotein and the other had 
positive LA and so satisfied the criteria of primary APS. This can explain the occurrence of this coronary event.  
  
Systemic arterial and venous thromboses are prominent and typical features of APS. Vianna et al [3] reported episodes of deep vein thrombosis in 
54% and arterial occlusions in 44% of cases. The major cardiac manifestations of APS include valve disease, myocardial infarction, intracardiac 
thrombus and myocardial microthrombosis [4] The frequency of myocardial infarction in patients with APS is reportedly 4%, and the presence of 
antiphospholipid antibodies has been associated with myocardial infarction in young patients. In a multicenter prospective Cohort of 1000 patients 
with APS, MI was the presenting manifestation in 2.8 % and appeared during the follow-up in 5,5% of the Cohort [5] There is an increased risk of 
myocardial infarction in patients with APS [6] caused by coronary thrombosis rather than by premature atherosclerosis. In table 1 we summarise 
reports of cases of antiphospholipid syndrome with myocardial infarction since the report of Harris [7,11-13,15-25]The actual mechanism of the 
thrombosis in APS is as yet unknown, but numerous mechanisms have been proposed. It has been attributed to inhibition of prekallikrein by the 
lupus anticoagulant or, as recently postulated, to interference with the activation of the protein C and protein S anti-coagulant pathways. Recent 
data show that the biding of certain autoantibodies to endothelial cells and platelets is dependent upon the presence of B2 glycoprotein I (B2GPI). 
Autoantibodies binding to B2GPI on the surface of endothelial cells induce expression of adhesion molecules and enhance monocyte adhesion to 
the endothelial cells [8] 
  
Current data are supporting an association between these autoantibodies and atherosclerosis as well. Human studies suggest that anti-cardiolipin 
antibodies  and  anti-beta2-glycoprotein-I  antibodies  are  elevated  in  patients  having  coronary  artery  disease  compared  with  controls  [9]  Anti-
cardiolipin  antibodies  are  also  associated  with  typical  chest  pain,  significant  coronary  artery  stenosis  on  angiography  and  are  predictive  of 
myocardial infarction. Laboratory studies and murine models support the pro-atherogenic role of these autoantibodies, as they are involved in 
uptake of oxidized LDL into macrophages, and immunization of mice with them results in enhanced atherosclerosis [9] There is some evidence that 
high anti-beta2-glycoprotein-I antibodies can present a risk factor for atherosclerosis, but more epidemiological data are required in order to 
confirm whether the pro-atherogenic properties of anti-phospholipid antibodies signifies an independent risk factor for atherosclerosis and its 
complications. Hamsten et al [10] studied 62 patients who were survivors of acute myocardial infarction under the age of 45, and found that 21% 
of these patients had anticardiolipin antibodies. In those surviving with positive antibodies, 61% experienced additional cardiovascular events in 
the  subsequent  5  years  compared  with  those  without  elevated  anticardiolipin  antibodies.  Mattila  et  al  [11]  demonstrated  an  increase  in 
anticardiolipin antibodies in 52% of patients within three months of an acute myocardial infarction. 
  
Thus, the interaction of these atherosclerotic and prothrombotic risk factors substantially increased the risk of myocardial infarction in the young 
patients.  Subjects  at  risk  of  developing  early  coronary  artery  disease  often  have  clustering  of  multiple  risk  factors  (case  2).The  optimal 
management  of  AMI  in  APS  is still  under  debate  [4] Primary  angioplasty  may  be  considered  the  treatment  of  choice  in  case  of  myocardial 
infarction. However, patients with APS have higher rates of complications after coronary angioplasty or CABG, such as early failure or recurrent 
coronary stent thrombosis [4] Anticoagulant therapy started immediately after the PTCA may contribute to cause long term coronary patency and 
to prevent acute stent occlusion. Therefore, long-term oral anticoagulant appeared to be effective. When thrombi are diffuse as in the second 
case, PTCA could not be done in emergency; intravenously platelet glycoprotein IIbIIIa receptor inhibitor may be effective. Fibrinolysis may be 
effective as initial treatment for acute thrombotic disorder including acute myocardial infarction (Harpaz et al and Ho et al) [12,13] 
  
When  patients  presented  catastrophic  antiphospholipid  syndrome  with  diffuse  thromboembolism  (like  our  second  case),  treatment  with 
methylprednisone under a broad spectrum of anti-infective therapy may be effective. We didn’t practice it in our case. More aggressive therapy 
modalities may be necessary to save the patient’s life, such as plasmapheresis, immunoglobulin and cyclophosphamide. 
  
For  chronic  management,  the  Committee  consensus  recommends  aggressive  treatment  of  all  risk  factors  for  atherosclerosis  (hypertension, 
hypercholesterolaemia,  and  smoking)  and  liberal  use  of  folic  acid,  B  vitamins  and  cholesterol-lowering  drugs  (preferably  statins)  in  patients 
suffering from APS. Hydroxychloroquine for cardiac protection in APS patients may be considered. The Committee also recommends warfarin 
anticoagulation for those who have a history of thrombosis in the absence of atherosclerosis, but it recognizes that developing data may support 
the use of antiplatelet agents instead. In presence of intracardiac thrombi, the Committee recommends intensive warfarin anticoagulation [14]; but Page number not for citation purposes  4 
in a recent study, high-intensity warfarin therapy (INR 3 to 4) was not superior to moderate-intensity warfarin for thromboprophylaxis in patients 
with APS and previous thrombosis [15] 
  
  
Conclusion 
  
Acute myocardial infarction is unusual in young adults; antiphospholipid syndrome may be one of the aetiologies. Thus, immunological tests should 
be performed (lupus anticoagulant, anticardiolipin antibodies…), especially when there is a history of recurrent foetal loss or in the presence of 
symptoms of an associated connective tissue disorder. In such a case, PTCA followed by antithrombotic therapy is effective when angiographic 
data  are  favourable.  Long  term  anticoagulant  and  antiplatelet  therapies  are  recommended.  Given  the  high  rate  of  mortality  of  catastrophic 
antiphospholipid syndrome in some cases, this report emphasizes the need for rapid diagnosis and effective multimodal treatment in an intensive 
care unit setting for these patients. 
  
  
Competing interests 
  
The authors declare no competing interests. 
  
  
Author’s contribution 
  
ICMJE authorship criteria met. All the authors contribute to the management of the patient and the writing up of the manuscript. The final version 
of the manuscript was reviewed and approved by all the authors. 
  
  
Tables and figures 
  
Table 1: Literature data of some cases report of antiphospholipid syndrome with acute myocardial infarction 
  
Figure 1: Left coronary arteriogram of a young patient with antiphospholipid syndrome and myocardial infarction on admission showing thrombotic 
stenosis of left descending coronary artery at the level of the proximal section 
  
Figure 2: Arteriogram of a young patient with antiphospholipid syndrome and myocardial infarction after PTCA showing evidence of successful 
recanalization 
  
Figure 3: Four-chamber view echocardiography of a young patient with antiphospholipid syndrome and myocardial infarction showing an apical 
large thrombus measuring 38x18 mm 
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Table 1: Literature data of some cases report of antiphospholipid syndrome with acute myocardial infarction 
 
Reference  Age  Sex  Lesion  Treatment  Other thrombosis 
           
Harpaz et al [11] 
  
40  M  Anterior  t-PA (iv)  Pulmonary embolism 
amaurosis fugax 
Kattwinkel et al [15]  29 
 
F 
 
Diffuse 
 
Conventional medical 
treatment 
 
Not described 
(recurrent fetal loss) 
Thorp et al [16]  29 
 
F 
 
Inferior 
 
Conventional medical 
treatment 
DVT 
Miller et al [17]  8 
 
F 
 
Lateral 
 
Resuscitation death 
 
Not described 
 
Ho et al [12] 
  
62 
 
M 
 
Anterior 
 
t-PA (iv) 
 
DVT 
 
Sakakibara et al [18] 
  
32 
 
F 
 
Inferior 
 
Conservative 
CABG 
 
Cerebral infarction 
 
Chambers et al [19] 
  
56 
 
F 
 
Inferior 
 
Streptokinase 
(iv) PTCA 
CABG 
 
Not described 
 
Kovacs et al [20]  56 
 
F 
 
Diffuse 
 
t-PA (iv) 
 
DVT 
 
Derksen et al [21] 
  
32 
 
F 
 
Anterior 
 
Conventional medical 
treatment 
DVT 
 
Susumu et al [22]  20  M  Inferior 
 
PTCA 
t-PA (iv) 
 
Not described 
 
Stoupakis et al [23]  32  M  Anterior 
 
PTCA 
 
Not described 
 
Ibrahim et al [24]  44  F  Inferior 
 
Surgery (mass excision)  Cerebral infarction 
 
Sajeev et al [25]  37  F  Anterior  Conventional medical 
treatment 
Not described 
(fetal loss) 
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